CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: BCAS3 (ImmuneEditome ID:54828)

1. Gene summary of enriched editing regions for BCAS3

check button Gene summary
Gene informationGene symbol

BCAS3

Gene ID

54828

GeneSynonymsGAOB1|HEMARS|MAAB|PHAF2
GeneCytomap

17q23.2

GeneTypeprotein-coding
GeneDescriptionBCAS3 microtubule associated cell migration factor|BCAS4/BCAS3 fusion|Rudhira|breast carcinoma amplified sequence 4/3 fusion protein|breast carcinoma-amplified sequence 3|metastasis associated antigen of breast cancer|phagophore assembly factor 2|protein Maab1
GeneModificationdate20230415
UniprotIDQ9H6U6;K7EQA6;K7EIR7;K7ELH0;K7EJH7;K7EJU7;K7ESE9;K7EML5;K7EKB0;K7EIE2
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr17:61094641-61096545:+ENST00000585979.4ENSG00000141376.19BCAS3ncRNA_intronicCharlie1b,AluSp,Charlie1a,AluSz,L1ME3,(AC)n,AluJr,AluSz6chr17:61094641-61096545:+.alignment
chr17:61166529-61166824:+ENST00000585812.4ENSG00000141376.19BCAS3ncRNA_intronicAluSz,AluJochr17:61166529-61166824:+.alignment
chr17:61166529-61166824:+ENST00000585979.4ENSG00000141376.19BCAS3ncRNA_intronicAluSz,AluJochr17:61166529-61166824:+.alignment
chr17:61166529-61166824:+ENST00000587294.4ENSG00000141376.19BCAS3ncRNA_intronicAluSz,AluJochr17:61166529-61166824:+.alignment
chr17:61175108-61176878:+ENST00000585812.4ENSG00000141376.19BCAS3ncRNA_intronicL1MA7,L1ME1,AluJo,(AT)n,AluJb,L1MEc,AluJr,(TATT)nchr17:61175108-61176878:+.alignment
chr17:61175108-61176878:+ENST00000585979.4ENSG00000141376.19BCAS3ncRNA_intronicL1MA7,L1ME1,AluJo,(AT)n,AluJb,L1MEc,AluJr,(TATT)nchr17:61175108-61176878:+.alignment
chr17:61175108-61176878:+ENST00000587294.4ENSG00000141376.19BCAS3ncRNA_intronicL1MA7,L1ME1,AluJo,(AT)n,AluJb,L1MEc,AluJr,(TATT)nchr17:61175108-61176878:+.alignment
chr17:61181035-61182143:+ENST00000585812.4ENSG00000141376.19BCAS3ncRNA_intronicAluJo,AluJrchr17:61181035-61182143:+.alignment
chr17:61181035-61182143:+ENST00000585979.4ENSG00000141376.19BCAS3ncRNA_intronicAluJo,AluJrchr17:61181035-61182143:+.alignment
chr17:61181035-61182143:+ENST00000587294.4ENSG00000141376.19BCAS3ncRNA_intronicAluJo,AluJrchr17:61181035-61182143:+.alignment
chr17:61190243-61195661:+ENST00000585812.4ENSG00000141376.19BCAS3ncRNA_intronic(AAAAG)n,L1MEi,AluY,AluSp,AluSx1,AluJr,AluJb,AluSz6,AluJo,AluSx,AluSq2chr17:61190243-61195661:+.alignment
chr17:61190243-61195661:+ENST00000585979.4ENSG00000141376.19BCAS3ncRNA_intronic(AAAAG)n,L1MEi,AluY,AluSp,AluSx1,AluJr,AluJb,AluSz6,AluJo,AluSx,AluSq2chr17:61190243-61195661:+.alignment
chr17:61190243-61195661:+ENST00000587294.4ENSG00000141376.19BCAS3ncRNA_intronic(AAAAG)n,L1MEi,AluY,AluSp,AluSx1,AluJr,AluJb,AluSz6,AluJo,AluSx,AluSq2chr17:61190243-61195661:+.alignment
chr17:61206487-61206782:+ENST00000585812.4ENSG00000141376.19BCAS3ncRNA_intronicAluSpchr17:61206487-61206782:+.alignment
chr17:61206487-61206782:+ENST00000585979.4ENSG00000141376.19BCAS3ncRNA_intronicAluSpchr17:61206487-61206782:+.alignment
chr17:61206487-61206782:+ENST00000587294.4ENSG00000141376.19BCAS3ncRNA_intronicAluSpchr17:61206487-61206782:+.alignment
chr17:61231718-61232174:+ENST00000585812.4ENSG00000141376.19BCAS3ncRNA_intronicAluJr,AluSg4chr17:61231718-61232174:+.alignment
chr17:61231718-61232174:+ENST00000585979.4ENSG00000141376.19BCAS3ncRNA_intronicAluJr,AluSg4chr17:61231718-61232174:+.alignment
chr17:61231718-61232174:+ENST00000587294.4ENSG00000141376.19BCAS3ncRNA_intronicAluJr,AluSg4chr17:61231718-61232174:+.alignment
chr17:61242116-61244814:+ENST00000585812.4ENSG00000141376.19BCAS3ncRNA_intronicL1ME4a,L1MA9,AluSp,AluY,AluSc,AluJrchr17:61242116-61244814:+.alignment
chr17:61242116-61244814:+ENST00000585979.4ENSG00000141376.19BCAS3ncRNA_intronicL1ME4a,L1MA9,AluSp,AluY,AluSc,AluJrchr17:61242116-61244814:+.alignment
chr17:61242116-61244814:+ENST00000587294.4ENSG00000141376.19BCAS3ncRNA_intronicL1ME4a,L1MA9,AluSp,AluY,AluSc,AluJrchr17:61242116-61244814:+.alignment
chr17:61246185-61246409:+ENST00000585812.4ENSG00000141376.19BCAS3ncRNA_intronicAluJbchr17:61246185-61246409:+.alignment
chr17:61246185-61246409:+ENST00000585979.4ENSG00000141376.19BCAS3ncRNA_intronicAluJbchr17:61246185-61246409:+.alignment
chr17:61246185-61246409:+ENST00000587294.4ENSG00000141376.19BCAS3ncRNA_intronicAluJbchr17:61246185-61246409:+.alignment
chr17:61246185-61246409:+ENST00000588569.1ENSG00000141376.19BCAS3ncRNA_intronicAluJbchr17:61246185-61246409:+.alignment
chr17:61246185-61246409:+ENST00000592702.4ENSG00000141376.19BCAS3ncRNA_intronicAluJbchr17:61246185-61246409:+.alignment
chr17:61264476-61265405:+ENST00000585812.4ENSG00000141376.19BCAS3ncRNA_intronicAluSx,L1ME3Cz,(GAGACAT)n,MIRb,AluSpchr17:61264476-61265405:+.alignment
chr17:61264476-61265405:+ENST00000585979.4ENSG00000141376.19BCAS3ncRNA_intronicAluSx,L1ME3Cz,(GAGACAT)n,MIRb,AluSpchr17:61264476-61265405:+.alignment
chr17:61264476-61265405:+ENST00000587294.4ENSG00000141376.19BCAS3ncRNA_intronicAluSx,L1ME3Cz,(GAGACAT)n,MIRb,AluSpchr17:61264476-61265405:+.alignment
chr17:61264476-61265405:+ENST00000588569.1ENSG00000141376.19BCAS3ncRNA_intronicAluSx,L1ME3Cz,(GAGACAT)n,MIRb,AluSpchr17:61264476-61265405:+.alignment
chr17:61264476-61265405:+ENST00000592702.4ENSG00000141376.19BCAS3ncRNA_intronicAluSx,L1ME3Cz,(GAGACAT)n,MIRb,AluSpchr17:61264476-61265405:+.alignment
chr17:61271878-61272629:+ENST00000585812.4ENSG00000141376.19BCAS3ncRNA_intronicAluJb,AluJr,Arthur1,L1MB2chr17:61271878-61272629:+.alignment
chr17:61271878-61272629:+ENST00000585979.4ENSG00000141376.19BCAS3ncRNA_intronicAluJb,AluJr,Arthur1,L1MB2chr17:61271878-61272629:+.alignment
chr17:61271878-61272629:+ENST00000587294.4ENSG00000141376.19BCAS3ncRNA_intronicAluJb,AluJr,Arthur1,L1MB2chr17:61271878-61272629:+.alignment
chr17:61271878-61272629:+ENST00000588569.1ENSG00000141376.19BCAS3ncRNA_intronicAluJb,AluJr,Arthur1,L1MB2chr17:61271878-61272629:+.alignment
chr17:61271878-61272629:+ENST00000592702.4ENSG00000141376.19BCAS3ncRNA_intronicAluJb,AluJr,Arthur1,L1MB2chr17:61271878-61272629:+.alignment
chr17:61276959-61277861:+ENST00000585812.4ENSG00000141376.19BCAS3ncRNA_intronicL1M4,AluJr4chr17:61276959-61277861:+.alignment
chr17:61276959-61277861:+ENST00000585979.4ENSG00000141376.19BCAS3ncRNA_intronicL1M4,AluJr4chr17:61276959-61277861:+.alignment
chr17:61276959-61277861:+ENST00000587294.4ENSG00000141376.19BCAS3ncRNA_intronicL1M4,AluJr4chr17:61276959-61277861:+.alignment
chr17:61276959-61277861:+ENST00000588569.1ENSG00000141376.19BCAS3ncRNA_intronicL1M4,AluJr4chr17:61276959-61277861:+.alignment
chr17:61276959-61277861:+ENST00000592702.4ENSG00000141376.19BCAS3ncRNA_intronicL1M4,AluJr4chr17:61276959-61277861:+.alignment
chr17:61298919-61299413:+ENST00000585812.4ENSG00000141376.19BCAS3ncRNA_intronicAluY,AluSx1chr17:61298919-61299413:+.alignment
chr17:61298919-61299413:+ENST00000585979.4ENSG00000141376.19BCAS3ncRNA_intronicAluY,AluSx1chr17:61298919-61299413:+.alignment
chr17:61298919-61299413:+ENST00000587294.4ENSG00000141376.19BCAS3ncRNA_intronicAluY,AluSx1chr17:61298919-61299413:+.alignment
chr17:61298919-61299413:+ENST00000588569.1ENSG00000141376.19BCAS3ncRNA_intronicAluY,AluSx1chr17:61298919-61299413:+.alignment
chr17:61298919-61299413:+ENST00000592702.4ENSG00000141376.19BCAS3ncRNA_intronicAluY,AluSx1chr17:61298919-61299413:+.alignment


Top

2. Tumor-specific enriched editing regions for BCAS3


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot
chr17:61190243-61195661:+OVCliEER3.7859e-021.0334e-020.3005image


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot

Top

3. Enriched editing regions and immune related genes for BCAS3


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr17:61175108-61176878:+ESCAEERENSG00000124444,ZNF576-0.45976.4932e-044.0307e-06-0.4149imageNACIN1;CSTF2T;DDX54;EIF4A3;FBL;FMR1;HNRNPL;IGF2BP1;IGF2BP2;IGF2BP3;KHSRP;NOP56;NOP58;RANGAP1;RBFOX2;SRSF1;SRSF3;TIA1;U2AF2;YTHDC1NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_DNA_REPAIR
chr17:61175108-61176878:+ESCAEERENSG00000124444,ZNF576-0.45976.4932e-044.0307e-06-0.4149imageNACIN1;CSTF2T;DDX54;EIF4A3;FBL;FMR1;HNRNPL;IGF2BP1;IGF2BP2;IGF2BP3;KHSRP;NOP56;NOP58;RANGAP1;RBFOX2;SRSF1;SRSF3;TIA1;U2AF2;YTHDC1NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_DNA_REPAIR
chr17:61175108-61176878:+ESCAEERENSG00000124444,ZNF576-0.45976.4932e-044.0307e-06-0.4149imageNACIN1;CSTF2T;DDX54;EIF4A3;FBL;FMR1;HNRNPL;IGF2BP1;IGF2BP2;IGF2BP3;KHSRP;NOP56;NOP58;RANGAP1;RBFOX2;SRSF1;SRSF3;TIA1;U2AF2;YTHDC1NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_DNA_REPAIR

More results



Top

4. Enriched editing regions and immune related splicing for BCAS3


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark

More results



Top

5. Enriched editing regions and immune infiltration for BCAS3


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
chr17:61175108-61176878:+BRCAEERB_cells_memory4.7299e-02-0.2184image
ENSG00000141376.19,BCAS3CESCEAGDendritic_cells_activated1.3925e-020.3160image
chr17:61175108-61176878:+ESCAEERT_cells_regulatory_(Tregs)2.2930e-03-0.2817image
chr17:61190243-61195661:+ESCAEERMonocytes2.0521e-02-0.2510image
chr17:61206487-61206782:+ESCAEERMacrophages_M11.3203e-050.6366image
chr17:61231718-61232174:+ESCAEERB_cells_naive1.5960e-030.4620image
chr17:61246185-61246409:+ESCAEERB_cells_memory4.7254e-020.3651image
chr17:61271878-61272629:+ESCAEERB_cells_naive8.2413e-03-0.4396image
chr17:61298919-61299413:+ESCAEERT_cells_regulatory_(Tregs)2.0111e-02-0.3807image
ENSG00000141376.19,BCAS3ESCAEAGT_cells_regulatory_(Tregs)1.5466e-03-0.2781image
ENSG00000141376.19,BCAS3HNSCEAGEosinophils2.0249e-030.4851image
chr17:61175108-61176878:+KIRCEERMast_cells_resting2.0941e-02-0.3835image
chr17:61175108-61176878:+KIRPEERNK_cells_resting4.7296e-030.3895image
ENSG00000141376.19,BCAS3KIRPEAGNK_cells_resting3.6574e-030.3998image
chr17:61175108-61176878:+LAMLEERNK_cells_activated5.8676e-030.4834image
ENSG00000141376.19,BCAS3LAMLEAGMast_cells_activated1.7418e-02-0.2501image
ENSG00000141376.19,BCAS3LGGEAGDendritic_cells_activated4.6911e-020.3857image
ENSG00000141376.19,BCAS3LIHCEAGMast_cells_resting3.6665e-020.4117image
ENSG00000141376.19,BCAS3LUADEAGMonocytes4.8785e-02-0.2381image
ENSG00000141376.19,BCAS3LUSCEAGMacrophages_M12.2795e-02-0.3549image
chr17:61175108-61176878:+OVEERMacrophages_M28.0786e-030.3670image
chr17:61190243-61195661:+OVEERMast_cells_activated4.1119e-020.2816image
ENSG00000141376.19,BCAS3OVEAGT_cells_gamma_delta6.6200e-030.2782image
chr17:61298919-61299413:+PRADEERT_cells_regulatory_(Tregs)4.1323e-02-0.3627image
ENSG00000141376.19,BCAS3PRADEAGT_cells_CD4_memory_activated3.2243e-030.2679image
chr17:61175108-61176878:+STADEERT_cells_follicular_helper5.5739e-040.2481image
chr17:61190243-61195661:+STADEERMonocytes2.1947e-02-0.2267image
chr17:61231718-61232174:+STADEERDendritic_cells_resting5.9152e-030.3666image
chr17:61242116-61244814:+STADEERPlasma_cells4.9091e-020.3975image
chr17:61246185-61246409:+STADEERNK_cells_resting2.0983e-020.3511image
chr17:61264476-61265405:+STADEERDendritic_cells_resting2.8915e-020.4658image
chr17:61271878-61272629:+STADEERT_cells_CD4_memory_activated4.0729e-030.3918image
ENSG00000141376.19,BCAS3STADEAGT_cells_follicular_helper5.8162e-030.1934image
ENSG00000141376.19,BCAS3UCECEAGDendritic_cells_resting1.4045e-020.4670image


Top

6. Enriched editing regions and immune gene sets for BCAS3


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
ENSG00000141376.19,BCAS3BLCAGSVA_HALLMARK_NOTCH_SIGNALINGEAG2.0974e-020.2123image
chr17:61175108-61176878:+BRCAGSVA_HALLMARK_GLYCOLYSISEER2.8269e-030.3238image
ENSG00000141376.19,BCAS3BRCAGSVA_HALLMARK_GLYCOLYSISEAG7.6480e-040.3429image
ENSG00000141376.19,BCAS3CESCGSVA_HALLMARK_PROTEIN_SECRETIONEAG1.8368e-020.3036image
chr17:61246185-61246409:+ESCAGSVA_HALLMARK_CHOLESTEROL_HOMEOSTASISEER1.0091e-020.4624image
ENSG00000141376.19,BCAS3ESCAGSVA_HALLMARK_APOPTOSISEAG8.1458e-030.2338image
chr17:61175108-61176878:+ESCAGSVA_HALLMARK_MTORC1_SIGNALINGEER2.1322e-020.2145image
chr17:61206487-61206782:+ESCAGSVA_HALLMARK_MTORC1_SIGNALINGEER8.4501e-030.4159image
ENSG00000141376.19,BCAS3HNSCGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEAG2.9701e-020.3530image
ENSG00000141376.19,BCAS3KIRCGSVA_HALLMARK_BILE_ACID_METABOLISMEAG4.7770e-020.3149image
chr17:61175108-61176878:+LAMLGSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSEEER3.4239e-02-0.3814image
ENSG00000141376.19,BCAS3LAMLGSVA_HALLMARK_PEROXISOMEEAG3.6894e-02-0.2204image
ENSG00000141376.19,BCAS3LGGGSVA_HALLMARK_HEDGEHOG_SIGNALINGEAG4.9392e-020.3818image
ENSG00000141376.19,BCAS3LIHCGSVA_HALLMARK_E2F_TARGETSEAG3.5250e-02-0.4145image
ENSG00000141376.19,BCAS3LUADGSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSEEAG4.9474e-050.4683image
ENSG00000141376.19,BCAS3OVGSVA_HALLMARK_MYC_TARGETS_V1EAG9.9522e-030.2646image
chr17:61190243-61195661:+OVGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEER1.6153e-030.4227image
chr17:61175108-61176878:+OVGSVA_HALLMARK_PI3K_AKT_MTOR_SIGNALINGEER4.1931e-030.3943image
ENSG00000141376.19,BCAS3PRADGSVA_HALLMARK_G2M_CHECKPOINTEAG4.9238e-040.3146image
chr17:61298919-61299413:+PRADGSVA_HALLMARK_PEROXISOMEEER4.1546e-020.3624image
chr17:61175108-61176878:+STADGSVA_HALLMARK_MYC_TARGETS_V2EER1.0854e-050.3132image
chr17:61271878-61272629:+STADGSVA_HALLMARK_GLYCOLYSISEER9.4435e-050.5148image
chr17:61246185-61246409:+STADGSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSEEER3.1439e-020.3286image
chr17:61242116-61244814:+STADGSVA_HALLMARK_PROTEIN_SECRETIONEER2.7379e-020.4409image
chr17:61190243-61195661:+STADGSVA_HALLMARK_P53_PATHWAYEER3.5142e-030.2864image
chr17:61298919-61299413:+STADGSVA_HALLMARK_NOTCH_SIGNALINGEER1.1645e-020.2918image
ENSG00000141376.19,BCAS3STADGSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSEEAG1.0270e-060.3358image
ENSG00000141376.19,BCAS3THCAGSVA_HALLMARK_HEDGEHOG_SIGNALINGEAG1.6261e-02-0.4953image
ENSG00000141376.19,BCAS3THYMGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALINGEAG3.5700e-02-0.4306image
ENSG00000141376.19,BCAS3UCECGSVA_HALLMARK_ADIPOGENESISEAG1.1720e-030.5909image


Top

7. Enriched editing regions and drugs for BCAS3


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
chr17:61175108-61176878:+BLCAAKT.inhibitor.VIIIEER6.4272e-030.2527image
ENSG00000141376.19,BCAS3BRCALenalidomideEAG2.6430e-020.2302image
ENSG00000141376.19,BCAS3CESCGW843682XEAG1.8608e-040.4643image
chr17:61246185-61246409:+ESCAIPA.3EER3.9887e-020.3772image
chr17:61190243-61195661:+ESCAMidostaurinEER4.4517e-030.3056image
chr17:61298919-61299413:+ESCABI.D1870EER1.9345e-02-0.3829image
ENSG00000141376.19,BCAS3ESCAAICAREAG4.9595e-03-0.2479image
chr17:61175108-61176878:+ESCAAICAREER7.0280e-03-0.2501image
chr17:61206487-61206782:+ESCACMKEER1.2295e-02-0.3972image
ENSG00000141376.19,BCAS3HNSCGefitinibEAG1.3773e-03-0.5197image
chr17:61175108-61176878:+KIRCMidostaurinEER1.9471e-020.3877image
chr17:61175108-61176878:+KIRPCI.1040EER4.5741e-020.2810image
ENSG00000141376.19,BCAS3KIRPCCT018159EAG3.6043e-02-0.2943image
ENSG00000141376.19,BCAS3LIHCCyclopamineEAG2.6320e-02-0.4527image
ENSG00000141376.19,BCAS3LUADElesclomolEAG4.0414e-04-0.4141image
ENSG00000141376.19,BCAS3LUSCAMG.706EAG1.8258e-02-0.3670image
chr17:61190243-61195661:+OVGW.441756EER1.9491e-03-0.4160image
chr17:61175108-61176878:+OVBortezomibEER7.2833e-03-0.3714image
chr17:61298919-61299413:+PRADBI.2536EER2.3026e-020.4008image
ENSG00000141376.19,BCAS3SKCMBIRB.0796EAG9.5178e-03-0.5080image
chr17:61175108-61176878:+STADGW.441756EER2.2409e-03-0.2205image
chr17:61264476-61265405:+STADEpothilone.BEER1.3971e-030.6381image
chr17:61206487-61206782:+STADCMKEER5.8270e-030.3519image
chr17:61271878-61272629:+STADAZD7762EER1.0911e-02-0.3503image
chr17:61242116-61244814:+STADAICAREER5.6651e-030.5368image
chr17:61190243-61195661:+STADDMOGEER2.7853e-020.2178image
chr17:61298919-61299413:+STADCMKEER2.1587e-020.2668image
ENSG00000141376.19,BCAS3STADGW.441756EAG6.3046e-03-0.1916image
ENSG00000141376.19,BCAS3THCAMetforminEAG3.0587e-03-0.5898image
ENSG00000141376.19,BCAS3UCECLenalidomideEAG1.1683e-020.4780image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType